NVAX Sep 2024 5.000 put
- Reuters
Novavax erases doubts about its ability to remain in business
In February last year, Novavax had raised doubts about its ability to remain in business and announced plans to slash spending as it worked to prepare for a fall vaccination campaign. The company also said on Friday that its revenue rose to $94 million in the first quarter, from $81 million in the same period in 2023.
- Reuters
CORRECTED-Novavax erases doubts about its ability to remain in business
COVID-19 vaccine maker Novavax , on Friday, erased doubts about its ability to remain in business by removing a so-called "going concern" notice. In February last year, Novavax had raised doubts about its ability to remain in business and announced plans to slash spending as it worked to prepare for a fall vaccination campaign.
- PR Newswire
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the first quarter ended March 31, 2024.
